802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia
← catalyst calendarSponsored by Biogen (industry) · BIIB — their whole pipeline →.
Phase
Phase 3
Status
Withdrawn
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
0actual
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor Decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-04-19 | estimated | When the study began enrolling |
| Primary completion | 2025-10-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-21 | estimated | The whole study's end, after follow-up |
| First posted | 2017-03-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2023-05-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Trigeminal Neuralgia
Interventions
- Drug: BIIB074 — also filed as CNV1014802
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants Classified as Responders at Week 12 of the Double-Blind Period
measured Week 12
Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) During the Long Term Extension (LTE) Period
measured Baseline up to Week 52
Permalink · BIIB's whole pipeline · Catalyst calendar · Every registered study · What changed